Merus NV
NASDAQ:MRUS

Watchlist Manager
Merus NV Logo
Merus NV
NASDAQ:MRUS
Watchlist
Price: 50.81 USD -0.24%
Market Cap: 3.5B USD
Have any thoughts about
Merus NV?
Write Note

Intrinsic Value

MRUS's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one MRUS stock under the Base Case scenario is 25.52 USD. Compared to the current market price of 50.81 USD, Merus NV is Overvalued by 50%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MRUS Intrinsic Value
25.52 USD
Overvaluation 50%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Merus NV

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for MRUS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about MRUS?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Merus NV

Provide an overview of the primary business activities
of Merus NV.

What unique competitive advantages
does Merus NV hold over its rivals?

What risks and challenges
does Merus NV face in the near future?

Has there been any significant insider trading activity
in Merus NV recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Merus NV.

Provide P/S
for Merus NV.

Provide P/E
for Merus NV.

Provide P/OCF
for Merus NV.

Provide P/FCFE
for Merus NV.

Provide P/B
for Merus NV.

Provide EV/S
for Merus NV.

Provide EV/GP
for Merus NV.

Provide EV/EBITDA
for Merus NV.

Provide EV/EBIT
for Merus NV.

Provide EV/OCF
for Merus NV.

Provide EV/FCFF
for Merus NV.

Provide EV/IC
for Merus NV.

Show me price targets
for Merus NV made by professional analysts.

What are the Revenue projections
for Merus NV?

How accurate were the past Revenue estimates
for Merus NV?

What are the Net Income projections
for Merus NV?

How accurate were the past Net Income estimates
for Merus NV?

What are the EPS projections
for Merus NV?

How accurate were the past EPS estimates
for Merus NV?

What are the EBIT projections
for Merus NV?

How accurate were the past EBIT estimates
for Merus NV?

Compare the revenue forecasts
for Merus NV with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Merus NV and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Merus NV against its competitors.

Analyze the profit margins
(gross, operating, and net) of Merus NV compared to its peers.

Compare the P/E ratios
of Merus NV against its peers.

Discuss the investment returns and shareholder value creation
comparing Merus NV with its peers.

Analyze the financial leverage
of Merus NV compared to its main competitors.

Show all profitability ratios
for Merus NV.

Provide ROE
for Merus NV.

Provide ROA
for Merus NV.

Provide ROIC
for Merus NV.

Provide ROCE
for Merus NV.

Provide Gross Margin
for Merus NV.

Provide Operating Margin
for Merus NV.

Provide Net Margin
for Merus NV.

Provide FCF Margin
for Merus NV.

Show all solvency ratios
for Merus NV.

Provide D/E Ratio
for Merus NV.

Provide D/A Ratio
for Merus NV.

Provide Interest Coverage Ratio
for Merus NV.

Provide Altman Z-Score Ratio
for Merus NV.

Provide Quick Ratio
for Merus NV.

Provide Current Ratio
for Merus NV.

Provide Cash Ratio
for Merus NV.

What is the historical Revenue growth
over the last 5 years for Merus NV?

What is the historical Net Income growth
over the last 5 years for Merus NV?

What is the current Free Cash Flow
of Merus NV?

Discuss the annual earnings per share (EPS)
trend over the past five years for Merus NV.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Merus NV

Current Assets 666.3m
Cash & Short-Term Investments 632.3m
Receivables 3.9m
Other Current Assets 30.1m
Non-Current Assets 178.4m
Long-Term Investments 150.6m
PP&E 22.5m
Intangibles 1.9m
Other Non-Current Assets 3.5m
Current Liabilities 80.1m
Accounts Payable 6.2m
Accrued Liabilities 38m
Other Current Liabilities 35.9m
Non-Current Liabilities 61.3m
Other Non-Current Liabilities 61.3m
Efficiency

Earnings Waterfall
Merus NV

Revenue
35.9m USD
Operating Expenses
-266.9m USD
Operating Income
-231m USD
Other Expenses
-13.6m USD
Net Income
-244.6m USD

Free Cash Flow Analysis
Merus NV

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

MRUS Profitability Score
Profitability Due Diligence

Merus NV's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
Exceptional Revenue Growth Forecast
ROE is Increasing
Negative 3-Years Revenue Growth
22/100
Profitability
Score

Merus NV's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

MRUS Solvency Score
Solvency Due Diligence

Merus NV's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Merus NV's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MRUS Price Targets Summary
Merus NV

Wall Street analysts forecast MRUS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MRUS is 90.78 USD with a low forecast of 67.67 USD and a high forecast of 116.55 USD.

Lowest
Price Target
67.67 USD
33% Upside
Average
Price Target
90.78 USD
79% Upside
Highest
Price Target
116.55 USD
129% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for MRUS?

Click here to dive deeper.

Dividends

Merus NV
does not pay dividends
Shareholder Yield

Current shareholder yield for MRUS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

MRUS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

MRUS News

Other Videos

Profile

Merus NV Logo
Merus NV

Country

Netherlands

Industry

Biotechnology

Market Cap

3.5B USD

Dividend Yield

0%

Description

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. The company is headquartered in Utrecht, Utrecht and currently employs 121 full-time employees. The company went IPO on 2016-05-19. The firm develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.

Contact

UTRECHT
Utrecht
Yalelaan 62
+31850162500.0
www.merus.nl

IPO

2016-05-19

Employees

121

Officers

CEO, President & Executive Director
Dr. Sven Ante Lundberg M.D.
Chief Financial Officer
Mr. Gregory D. Perry
EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal
Mr. Peter B. Silverman J.D.
Consultant
Dr. Andrew Joe M.D.
Co-Founder and Scientific Advisor
Dr. Hennie Hoogenboom
Chief Accounting Officer
Harry Shuman
Show More
CTO & Executive VP
Mr. Cornelis Adriaan de Kruif Ph.D.
Chief Scientific Officer & Senior VP
Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.
IR & Corporate Communications Officer
Kathleen Farren
Executive VP, Chief Development Officer & Head of Merus Utrecht
Mr. Alexander Berthold Hendrik Bakker Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one MRUS stock?

The intrinsic value of one MRUS stock under the Base Case scenario is 25.52 USD.

Is MRUS stock undervalued or overvalued?

Compared to the current market price of 50.81 USD, Merus NV is Overvalued by 50%.

Back to Top